Anaplastic astrocytoma in adults.

Details

Serval ID
serval:BIB_14684230FF80
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Anaplastic astrocytoma in adults.
Journal
Critical reviews in Oncology/Hematology
Author(s)
Stupp R., Reni M., Gatta G., Mazza E., Vecht C.
ISSN
1040-8428
Publication state
Published
Issued date
2007
Peer-reviewed
Oui
Volume
63
Number
1
Pages
72-80
Language
english
Notes
Publication types: Comparative Study ; Journal Article ; Review
Abstract
Anaplastic astrocytoma is an uncommon disease in the adult population. Prognosis is influenced by age, symptom duration, mental status and Karnofsky performance status. A truly complete resection, which is a recognized independent prognostic factor, is not possible and recurrence in the surgical cavity is common. Based on randomized data available, chemotherapy has consistently failed to improve the outcome of patients with anaplastic astrocytoma, while a meta-analysis showed a small, but significant improvement in survival favouring the use of chemotherapy. Outside a clinical trial, postoperative radiotherapy (30 x 2 Gy) remains the standard adjuvant therapy for most patients. For elderly patients, the application of treatment is usually based on performance status and neurological function. In recurrent disease, chemotherapy with temozolomide has been proven to be active and well-tolerated in phase II trials, but no comparative phase III trials of other cytotoxic drugs have been conducted.
Keywords
Adolescent, Adult, Aged, Antineoplastic Agents, Alkylating, Astrocytoma, Brain Neoplasms, Clinical Trials as Topic, Clinical Trials, Phase II as Topic, Dacarbazine, Female, Humans, Incidence, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Risk Factors, Survival Analysis
Pubmed
Web of science
Create date
28/01/2008 8:39
Last modification date
20/08/2019 12:43
Usage data